Regulatory incentives and enticing scientific discoveries are reinvigorating antibiotic development. The start-ups getting funded these days say they can boost the odds of clinical success, and reduce the cost of achieving it.
EnBiotix Inc. is focused on two anti-infective platforms: one an approach to revitalizing existing antibiotics, and the second a means of empowering phages, viruses that are natural enemies of...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?